Dr. Harshman on Earlier Use of Immunotherapy in RCC – OncLive
OncLive |
Dr. Harshman on Earlier Use of Immunotherapy in RCC
OncLive Harshman says that the next step in the treatment of patients with RCC is moving immunotherapy into earlier lines of treatment. Investigators are currently testing checkpoint inhibitors such as atezolizumab (Tecentriq) and pembrolizumab (Keytruda). In … |
